Myriad Genetics (MYGN) Tops Q3 EPS by 4c, Raises Guidance

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.27, $0.04 better than the analyst estimate of $0.23. Revenue for the quarter came in at $196.9 million versus the consensus estimate of $189.1 million.

GUIDANCE:

Myriad Genetics sees Q4 2017 EPS of $0.26-$0.28. Myriad Genetics sees Q4 2017 revenue of $192-194 million.

Myriad Genetics sees FY 2017 EPS of $1.01-$1.03 Myriad Genetics sees FY 2017 revenue of $763-765 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Keefe, Bruyette & Woods Starts Columbia Financial Inc (CLBK) at Outperform
• Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'